United StatesAmgen, a biotechnology company, has increased its full-year revenue forecast to between $38.2 billion and $39.4 billion following a 10% increase in second-quarter revenue, which reached $10.1 billion. This update comes after the company exceeded expectations in its financial performance. The decision to raise its outlook reflects confidence in its current business trajectory and potential future growth. Amgen also announced that it has decided to discontinue development of a weight loss drug, likely due to strategic or financial considerations.
Bias read (Center): The article discusses a corporate financial update and a strategic business decision regarding a drug discontinuation. There is no mention of political figures, policies, or contentious issues, making the content apolitical. The framing is neutral, focusing solely on financial performance and market
